1. Influence of TP53 mutation on efficacy and survival in advanced EGFR‐mutant non‐small cell lung cancer patients treated with third‐generation EGFR tyrosine kinase inhibitors
   Zhonghan Zhang et al, 2024, MedComm CrossRef
2. Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase
   Mohd Rehan et al, 2024, Frontiers in Pharmacology CrossRef
3. Основанные на молекулярном пути EGFR генные подписи клинически значимых мутаций при раке молочной железы, легких, щитовидной железы и при меланоме
   М. Раевский et al, 2021, Биохимия CrossRef
4. Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma
   Ji-wen Huo et al, 2022, Frontiers in Oncology CrossRef
5. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
   Ullas Batra et al, 2023, BMJ Open Respiratory Research CrossRef
6. Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification
   Sara Boukansa et al, 2022, Cancer Control CrossRef
7. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
   Juanjuan Dong et al, 2021, Cancer Management and Research CrossRef
8. EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers
   Mikhail Raevskiy et al, 2021, Biochemistry (Moscow) CrossRef